Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 2
2020 2
2021 1
2022 3
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
AKT mutant allele-specific activation dictates pharmacologic sensitivities.
Shrestha Bhattarai T, Shamu T, Gorelick AN, Chang MT, Chakravarty D, Gavrila EI, Donoghue MTA, Gao J, Patel S, Gao SP, Reynolds MH, Phillips SM, Soumerai T, Abida W, Hyman DM, Schram AM, Solit DB, Smyth LM, Taylor BS. Shrestha Bhattarai T, et al. Among authors: gavrila ei. Nat Commun. 2022 Apr 19;13(1):2111. doi: 10.1038/s41467-022-29638-1. Nat Commun. 2022. PMID: 35440569 Free PMC article. Clinical Trial.
Exceptional response to cetuximab monotherapy after failure of immunotherapy with a checkpoint inhibitor in a patient with metastatic head and neck squamous cell cancer: case report and review of the literature.
Bloomer CH, Gavrila E, Burcher KM, Kalada JM, Chang MJ, Gebeyehu RR, Asare E, Khoury LM, Kinney R, Frizzell B, Sullivan CA, Bunch PM, Porosnicu M. Bloomer CH, et al. Among authors: gavrila e. Ther Adv Med Oncol. 2023 Aug 31;15:17588359231193722. doi: 10.1177/17588359231193722. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37667781 Free PMC article.
Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis.
Taylor J, Sendino M, Gorelick AN, Pastore A, Chang MT, Penson AV, Gavrila EI, Stewart C, Melnik EM, Herrejon Chavez F, Bitner L, Yoshimi A, Lee SC, Inoue D, Liu B, Zhang XJ, Mato AR, Dogan A, Kharas MG, Chen Y, Wang D, Soni RK, Hendrickson RC, Prieto G, Rodriguez JA, Taylor BS, Abdel-Wahab O. Taylor J, et al. Among authors: gavrila ei. Cancer Discov. 2019 Oct;9(10):1452-1467. doi: 10.1158/2159-8290.CD-19-0298. Epub 2019 Jul 8. Cancer Discov. 2019. PMID: 31285298 Free PMC article.
Serendipitous synergism - an exceptional response to treatment with pembrolizumab in the course of a natural immunovirotherapy: a case report and review of the literature.
Khoury LM, Burcher KM, Ng RT, Song AH, Chang MJ, Gavrila E, Bloomer CH, Robinson MB, Kouri BE, Waltonen JD, Bunch PM, Lauer UM, Porosnicu M. Khoury LM, et al. Among authors: gavrila e. Ther Adv Med Oncol. 2022 Oct 20;14:17588359221122729. doi: 10.1177/17588359221122729. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 36312814 Free PMC article.
Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer.
Smyth LM, Piha-Paul SA, Won HH, Schram AM, Saura C, Loi S, Lu J, Shapiro GI, Juric D, Mayer IA, Arteaga CL, de la Fuente MI, Brufksy AM, Spanggaard I, Mau-Sørensen M, Arnedos M, Moreno V, Boni V, Sohn J, Schwartzberg LS, Gonzàlez-Farré X, Cervantes A, Bidard FC, Gorelick AN, Lanman RB, Nagy RJ, Ulaner GA, Chandarlapaty S, Jhaveri K, Gavrila EI, Zimel C, Selcuklu SD, Melcer M, Samoila A, Cai Y, Scaltriti M, Mann G, Xu F, Eli LD, Dujka M, Lalani AS, Bryce R, Baselga J, Taylor BS, Solit DB, Meric-Bernstam F, Hyman DM. Smyth LM, et al. Among authors: gavrila ei. Cancer Discov. 2020 Feb;10(2):198-213. doi: 10.1158/2159-8290.CD-19-0966. Epub 2019 Dec 5. Cancer Discov. 2020. PMID: 31806627 Free PMC article. Clinical Trial.
Leveraging Systematic Functional Analysis to Benchmark an In Silico Framework Distinguishes Driver from Passenger MEK Mutants in Cancer.
Hanrahan AJ, Sylvester BE, Chang MT, Elzein A, Gao J, Han W, Liu Y, Xu D, Gao SP, Gorelick AN, Jones AM, Kiliti AJ, Nissan MH, Nimura CA, Poteshman AN, Yao Z, Gao Y, Hu W, Wise HC, Gavrila EI, Shoushtari AN, Tiwari S, Viale A, Abdel-Wahab O, Merghoub T, Berger MF, Rosen N, Taylor BS, Solit DB. Hanrahan AJ, et al. Among authors: gavrila ei. Cancer Res. 2020 Oct 1;80(19):4233-4243. doi: 10.1158/0008-5472.CAN-20-0865. Epub 2020 Jul 8. Cancer Res. 2020. PMID: 32641410 Free PMC article.
Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma.
Burcher KM, Lantz JW, Gavrila E, Abreu A, Burcher JT, Faucheux AT, Xie A, Jackson C, Song AH, Hughes RT, Lycan T Jr, Bunch PM, Furdui CM, Topaloglu U, D'Agostino RB Jr, Zhang W, Porosnicu M. Burcher KM, et al. Among authors: gavrila e. Cancers (Basel). 2021 Nov 16;13(22):5733. doi: 10.3390/cancers13225733. Cancers (Basel). 2021. PMID: 34830888 Free PMC article.
Study protocol: phase II study to evaluate the effect of cetuximab monotherapy after immunotherapy with PD-1 inhibitors in patients with head and neck squamous cell cancer.
Burcher KM, Bloomer CH, Gavrila E, Kalada JM, Chang MJ, Gebeyehu RR, Song AH, Khoury LM, Lycan TW, Kinney R, D'Agostino R Jr, Bunch PM, Shukla K, Triozzi P, Furdui CM, Zhang W, Porosnicu M. Burcher KM, et al. Among authors: gavrila e. Ther Adv Med Oncol. 2024 Jan 19;16:17588359231217959. doi: 10.1177/17588359231217959. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 38249330 Free PMC article.